Chen Xiangbo, Liu Wenguang, Liu Bao
Key Laboratory of Molecular Epigenetics of the Ministry of Education (MOE), Northeast Normal University, Changchun, China.
Front Oncol. 2021 Apr 29;11:656132. doi: 10.3389/fonc.2021.656132. eCollection 2021.
It is reported that ginsenosides have a significant anti-tumor effect on a variety of tumors. However, the role and mechanism of Rh7 in non-small cell lung cancer (NSCLC) are unclear. In this study, we aimed to study the anti-tumor effect of Rh7 on the proliferation and progression of NSCLC. Bioinformatics analysis showed that ILF3-AS1 was regulated by ginsenoside Rh7 in NSCLC. Down-regulation of ILF3-AS1 could significantly inhibit the proliferation, metastasis and invasion of NSCLC. In addition, ILF3-AS1 negatively controlled miR-212, which in turn targeted SMAD1 expression, thereby regulating NSCLC cell viability and apoptosis. Our results indicate that ILF3-AS1 can be used as a diagnostic and therapeutic target for non-small cell lung cancer. It is discovered for the first time that ginsenoside Rh7 inhibits the expression of ILF3-AS1 and exerts antitumor effects.
据报道，人参皂苷对多种肿瘤具有显著的抗肿瘤作用。然而，Rh7在非小细胞肺癌（NSCLC）中的作用及机制尚不清楚。在本研究中，我们旨在研究Rh7对NSCLC增殖和进展的抗肿瘤作用。生物信息学分析表明，在NSCLC中，ILF3-AS1受人参皂苷Rh7调控。ILF3-AS1的下调可显著抑制NSCLC的增殖、转移和侵袭。此外，ILF3-AS1负调控miR-212，而miR-212反过来靶向SMAD1的表达，从而调节NSCLC细胞的活力和凋亡。我们的结果表明，ILF3-AS1可作为非小细胞肺癌的诊断和治疗靶点。首次发现人参皂苷Rh7抑制ILF3-AS1的表达并发挥抗肿瘤作用。
